Key result
HAART regimens, especially protease inhibitors, promote metabolic syndrome and may heighten cardiovascular disease risk.
Answers are grounded in this paper and cite their sources.
Highly active antiretroviral therapy (HAART) regimens, especially those including protease inhibitors have been shown to cause, in a high proportion of HIV-infected patients, a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease. A careful stratification of the cardiovascular risk of HIVinfected patients under HAART is needed according to the most recent clinical guidelines.
No takes yet. Share an insight, caveat, or question.
Giuseppe Bárbaro (2005) conducted a review in HIV infection. Highly active antiretroviral therapy (HAART), especially protease inhibitors was evaluated on Metabolic syndrome and cardiovascular disease. Highly active antiretroviral therapy regimens, especially protease inhibitors, cause metabolic syndrome and may increase cardiovascular disease risk in HIV-infected patients.
Synapse has enriched 10 related papers. Consider them for comparative context: